Stock Events

Stock Events

Madrigal Pharmaceuticals 

€430.9
64
+€0.9+0.21% Today

Statistics

Day High
432
Day Low
425.4
52W High
519.6
52W Low
229.6
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q4 2025
Q1 2026
Next
-3.61
-2.66
-1.71
-0.76
Expected EPS
-1.03902707331
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YDO1.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with Madrigal's NASH treatments.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong focus on liver diseases, including NASH, positioning it as a competitor in the same therapeutic area as Madrigal.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.77M
Galmed Pharmaceuticals is developing treatments for liver diseases, including NASH, making it a direct competitor to Madrigal.
Agios Pharmaceuticals
AGIO
Mkt Cap1.67B
Agios Pharmaceuticals focuses on metabolic disorders, competing in the same space as Madrigal's treatments for liver diseases.
Axsome Therapeutics
AXSM
Mkt Cap10.62B
Axsome Therapeutics, while primarily focused on CNS disorders, has interests in metabolic disorders, potentially putting it in competition with Madrigal.
Novartis
NVS
Mkt Cap279.67B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for liver diseases, making it a potential competitor to Madrigal in the NASH space.

About

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Show more...
CEO
Mr. William J. Sibold
Employees
915
Country
United States
ISIN
US5588681057

Listings

MI
IT
1MDGL.MI
MU
DE
YDO1.MU
STU
DE
YDO1.STU
LSE
GB
0JXI.LSE

0 Comments

Share your thoughts

FAQ

What is Madrigal Pharmaceuticals stock price today?▼
The current price of YDO1.STU is €430.9 EUR — it has increased by +0.21% in the past 24 hours. Watch Madrigal Pharmaceuticals stock price performance more closely on the chart.
What is Madrigal Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Madrigal Pharmaceuticals stocks are traded under the ticker YDO1.STU.
Is Madrigal Pharmaceuticals stock price growing?▼
YDO1.STU stock has fallen by -3.24% compared to the previous week, the month change is a -9.5% fall, over the last year Madrigal Pharmaceuticals has showed a +64.93% increase.
When is the next Madrigal Pharmaceuticals earnings date?▼
Madrigal Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Madrigal Pharmaceuticals earnings last quarter?▼
YDO1.STU earnings for the last quarter are -2.77 EUR per share, whereas the estimation was -3.61 EUR resulting in a +23.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Madrigal Pharmaceuticals have?▼
As of May 06, 2026, the company has 915 employees.
In which sector is Madrigal Pharmaceuticals located?▼
Madrigal Pharmaceuticals operates in the Energy sector.
When did Madrigal Pharmaceuticals complete a stock split?▼
Madrigal Pharmaceuticals has not had any recent stock splits.
Where is Madrigal Pharmaceuticals headquartered?▼
Madrigal Pharmaceuticals is headquartered in West Conshohocken, United States.